Phase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumors & Lymphoma

NCT03061188 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

15

Enrollment

OTHER

Sponsor class

Conditions

Advanced Solid Neoplasm
Aggressive Non-Hodgkin Lymphoma
Recurrent Solid Neoplasm
Refractory Mantle Cell Lymphoma
T-Cell Non-Hodgkin Lymphoma
Unresectable Solid Neoplasm

Interventions

OTHER: Laboratory Biomarker Analysis
BIOLOGICAL: Nivolumab
OTHER: Pharmacological Study
DRUG: Veliparib

Sponsor

Northwestern University

Collaborators

[object Object]
[object Object]
[object Object]